Overview
- GLP-1 receptor agonists such as semaglutide have driven substantial average weight loss for many patients, with trials and real-world reports showing large mean reductions in body weight.
- A meaningful minority—estimated at roughly 10–30%—show minimal weight loss on therapy, a group commonly labeled 'non-responders'.
- High early dropout and underdosing limit real-world benefit, with studies reporting many patients stop treatment within the first year for reasons including side effects, cost, and suboptimal use.
- Researchers and clinicians point to genetic differences (for example variants in PAM and GLP-1R/GIPR), metabolic state, sleep, other medicines, and eating-behavior drivers as causes of variable response, which supports development of precision diagnostics and combined behavioral care.
- Experts at health conferences say rapid uptake has exposed stark access gaps and strained clinics, and they argue digital care, multidisciplinary supports, and a growing drug pipeline will be needed to control costs, preserve muscle and nutrition, and sustain long-term benefits for patients.